Lipoic acid as a rescue agent for adriamycin-induced hyperlipidemic nephropathy in rats

Nutrition Research

Volumn 23, Issue 4, 2003, Pages 539-548

  Malarkodi, K P ^a   Varalakshmi, P ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Adriamycin; Hyperlipidemia; Lipoic acid; Lipoproteins

Indexed keywords

CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER; CHOLESTEROL ESTERASE; DOXORUBICIN; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; THIOCTIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEEDING; HYPERLIPIDEMIA; KIDNEY DISEASE; KIDNEY MASS; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

EID: 0038076159     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0271-5317(03)00004-6     Document Type: Article

References (52)

1. Sumathi R, Jayanthi S, Varalakshmi P. Impaired lipid metabolism in calcium oxalate stone forming rats and DL-α-lipoic acid supplementation. Nutr Res 1995;15:59-70.
2. Dawidowicz EA. Dynamics of membrane lipid metabolism and turnover. Ann Rev Biochem 1987;56:43-61.
3. Van den Branden C, Ceyssens B, De Craemer D, Pauwels M, Vanden Houte K, De Bleser P, Hellemans K, Geerts A, Verbeelen D. Renal antioxidant enzymes and fibrosis-related markers in the rat adriamycin model. Nephron 2000;86:167-75.
4. Tritton TR, Murphere SA, Sarotorelli AC. Characterization of drug-membrane interactions using the liposome system. Biochem Pharmacol 1977;26:2319-23.
5. Hutchison FN. Proteinuria, hyperlipidemia and the kidney. Miner Electrolyte Metab 1993;19:127-36.
6. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo interstitial disease. Lancet 1982;2:1309-11.
7. French JW, Yamanaka BS, Ostwald R. Dietary induced glomerulosclerosis in the guinea pig. Arch Pathol 1967;83:204-20.
8. Kokui K, Yoshikawa N, Nakamura H, Itoh H. Cyclosporin reduces proteinuria in rats with aminonucleoside nephrosis. J Pathol 1992;166:297-301.
9. Bizzi A, Ceriani L, Gerundino M, Spina A, Tacconi MT, Veneroni E. Adriamycin causes hyperlipemia as a consequence of nephrotoxicity. Toxicol Lett 1983;18:291-300.
10. Song H, Li X, Zhu C, Wei M. Glomerulosclerosis in adriamycin-induced nephrosis is accelerated by a lipid rich diet. Pediatr Nephrol 2000;15:196-200.
11. Wagh SS, Nataraj CV, Menon KKG. Mode of action of lipoic acid in diabetes. J Biosci 1987;11:59-74.
12. Kagan V, Khan S, Swanson C, Shvedova A, Serbinova E, Packer L. Antioxidant action of thioctic acid and dihydrolipoic acid. Free Radic Biol Med 1990;9:15.
13. Podda M, Weber C, Traber M, Packer L. Simultaneous determination of tissue tocopherols, tocotrienols, ubiquinols and ubiquinones. J Lipid Res 1996;37:893-901.
14. Jayanthi S, Varalakshmi P. Tissue lipids in experimental calcium oxalate lithiasis and the effect of DL-α-lipoic acid. Biochem Int 1992;26:913-21.
15. McCarthy MF. An expanded concept of 'insurance' supplementation. Broad spectrum protection from cardiovascular disease. Med Hypoth 1981;7:1287-302.
16. Vodowich VP, Buko VO. Influence of the vitamin B complex on the content of saturated and unsaturated fattyacids in the blood of patients with coronary heart disease and essential hypertension. Vopr Pitan 1986;2:9-11.
17. Packer L, Witt EH, Tritschler HJ. Alpha lipoic acid as a biological antioxidant. Free Radic Biol Med 1995;19:227-50.
18. Herman EH, el-Hage A, Ferrans VJ. Protective effect of ICRF- 187 on doxorubiun-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (wky rats). Toxicol Appl Pharmacol 1988;92:42-53.
19. Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-509.
20. Jung DH. Cholesterol determination with ferric acetate-uranium acetate and sulfuric acid-ferrous sulfate reagents. Clin Chem 1970;42:1423-7.
21. Sperry WM, Webb A. A revision of the schoenheimer-sperry method for cholesterol determination. J Biol Chem 1950;187:97-106.
22. Rouser G, Fleischer S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorous analysis of spots. Lipids 1970;5:494-6.
23. Horn WT, Menahan LA. A sensitive method for the determination of free fattyacids in plasma. J Lipid Res 1981;22:377-81.
24. Wilson DF, Spiger MJ. A dual precipitation method for quantitative plasma lipoprotein measurement without ultracentrifugation. J Lab Clin Med 1973;82:473-82.
25. Kothari HV, Banner MJ, Miller BF. Cholesterol ester hydrolase in homogenates of lysosomal fractions of human aorta. Biochim Biophys Acta 1970;202:325-31.
26. Kritchevsky D, Kothari HV. Aortic cholesterol esterase: studies in white carneau and show racer pigeons. Biochim Biophys Act 1973;326:489-91.
27. Kothari HV, Miller BF, Kritchevsky. Aortic cholesterol esterase: characteristics of normal rat and rabbit enzyme. Biochim Biophys Acta 1973;296:446-54.
28. Schmidt A. Measurement of lipoprotein lipase and hepatic triglyceride lipase in human postheparin plasma. Methods Enzymol 1974;72:325-37.
29. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurements with folin-phenol reagent. J Biol Chem 1951;193:265-75.
30. Blum RH, Carter SK. Adriamycin - a new anticancer drug with significant clinical activity. Ann Interm Med 1974;80:249.
31. Goomarghtigh E, Chatelain P, Caspers J, Ruysschaert TM. Evidence of a specific complex between adriamycin and negatively charged phospholipids. Biochim Biophys Acta 1980;597:1-14.
32. Keane WF. Lipids and the kidney. Kidney Int 1994;46:910-20.
33. Manabe N, Kinoshita A, Yamaguchi M, Faruya Y, Nagano N, Yamada-uchio K, Akashi N, Miyamoto-Kuramitsu K, Miyamoto H. Changes in quantitative profile of extracellular matrix components in the kidneys of rats with adriamycin induced nephropathy. J Vet Med Sci 2001;63:125-33.
34. Venkatesan N, Venkatesan P, Karthikeyan J, Venkatesan A. Protection of taurine against adriamycin-induced proteinuria and hyperlipidemia in rats. Proc Soc Exp Biol Med 1997;215:158-64.
35. Stryer L. Biosynthesis of membrane lipids and steroid hormones. In: Stryer L, editor. Biochemistry. W.H. Freeman and Co., New. York, p. 547-74.
36. Montilla PL, Tunez IF, Munoz de Agueda C, Gascon FL, Soria JV. Protective effect of melatonin and retinol palmitate in oxidative stress and hyperlipidemic nephropathy induced by adriamyan in rat. J Pineal Res 1998;25:86-93.
37. Iliskovic N, Li T, Khaper N, Palace V, Singal PK. Modulation of adriamycin-induced changes in serum free fattyacids albumin and cardiac oxidative stress. Mol Cell Biochem 1998;188:161-6.
38. Angelucci L, Mascitelli-Coriandoli E. Anti-cholesterol activity of a-lipoic acid. Nature 1958;181:911-5.
39. Lukomskii PE. The effect of heparinoid (arteroid) lipoic acid and phenoxol on lipid and protein metabolism in patients with coronary atherosclerosis. Tr Mosk Gor Nauchn 1964;10:31-7.
40. Barter PJ, Nestel PJ, Carroll KF. Precursors of plasma triglyceride fatty acid in humans. Effects of glucose consumption, clofibrate administration and alcoholic fatty liver. Metabolism 1972;21:117-21.
41. Hong YM, Kim HS, Yoon HR. Serum lipid and fatty acid profiles in adriamycin-treated rats after administration of L-carnitine. Pediatr Res 2002;51:249-55.
42. Calandra S, Tarugi P, Ghisellini M, Gheradi E. Plasma and urine lipoproteins during the development of nephrotic syndrome induced in the rat by adriamycin. Exp Mol Pathol 1983;39:282-99.
43. Short CD, Durrington PN, Mallick NP, Hunt LP, Tetlow L, Ishola M. Serum and urinary high density lipoprotein in glomerular disease with proteinuria. Kidney Int 1986;29:1224-8.
44. Newmark SR, Anderson CF, Donadio JV, Ellefson RD. Lipoprotein profiles in adult nephrotics. Mayo Clin Proc 1975;50:359-64.
45. Sasaki J, Hara F, Motooka T, Naito S, Arakawa K. Nephrotic syndrome associated with hyper-high density lipoproteinemia potentiated by prednisolone therapy. Nephron 1985;41:110-3.
46. Montilla P, Tunez I, Munoz MC, López A, Soria JV. Hyperlipidemic nephropathy induced by adriamycin: effect of melatonin administration. Nephron 1997;76:345-50.
47. Thayer S. Decreased cardiac lipoprotein lipase activity in rats treated chronically with adriamycin. Life Sci 1985;36:635-41.
48. Mc Carty MF. Orthomolecular acids for dieting. Med Hypoth 1982;8:269-74.
49. Cattaneo R, Levi E, Prinotti C. Thioctic acid and modifications of some aspects of the lipid metabolism in patients with cardioangiopathies and atherosclerosis. Acta Gerontol 1959;8:123-30.
50. Nikkila EA. Metabolic regulation of plasma high density lipoprotein concentrations. Eur J Clin Invest 1978;8:111-3.
51. Venkatesn N, Punithavathy D, Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol 2000;129:231-4.
52. Debusk BG, Williams RJ. Effect of lipoic acid on the growth rate of young rats. Arch Biochem Biophys 1955;55:587-91.